EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immulina® mitigates the development of illness when administered during the prodromal period of influenza viral infection in mice (Part 2)

Tahir M Mir, Kashif Shamim, Jin Zhang, Shabana I Khan, Siddharth K Tripathi, Ikhlas A Khan, Gailen D Marshall, Mohammad K Ashfaq, Nirmal D Pugh

Phytomedicine · 2024

DOI: 10.1016/j.phymed.2024.155778 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024. Verfasst von Tahir M Mir und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, Universi…. Hauptthemen laut MEDLINE: Orthomyxoviridae Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCCIH NIH HHS, National Institutes of Health, National Center for Complementary and Integrative Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immulina®, a dietary supplement derived from Limnospira (formerly Arthrospira), is being investigated as a potential agent to increase antiviral resilience. In our recently published manuscript, we described the effects of Immulina® on influenza when taken daily, beginning before infection (prophylaxis) or after the onset of clinical symptoms of viral illness (therapeutic). However, the benefit of Immulina® in infected individuals before the manifestation of any symptoms (prodromal) has not been investigated yet. PURPOSE: To evaluate Immulina®'s potential use to increase the host antiviral immune response using a prodromal therapy regime. STUDY DESIGN: The efficacy of Immulina® extract was evaluated in rodents using a prodromal protocol (test material administered prior to the emergence of viral illness symptoms). METHODS: Immulina® (25, 50 and 100 mg/kg body weight) was orally administered to both genders of mice, 2 h following influenza A viral infection, and continued daily for 14 days. RESULTS: Compared to the infected control mice, animals fed Immulina® exhibited statistically significant reduction in the emergence of various physical symptoms of viral-induced illness and decreased viral RNA levels. The effects are likely mediated through the host immune system since the level of various cytokines (IL-6 and IFN-γ) were significantly increased in lung tissue. CONCLUSION: This study, together with our previous paper, indicate that Immulina® was most effective at enhancing immune antiviral resilience if administered before or soon after initial infection. The data generated can be used to guide additional research using human subjects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orthomyxoviridae InfectionsAnimalsFemaleMaleMiceAntiviral AgentsInterferon-gammaMice, Inbred BALB CDietary SupplementsLungInfluenza A virusCyanobacteriaProdromal Symptoms

Stichwörter der Autor:innen

ArthrospiraImmune resilienceInfluenza A (H1N1) virusProdromeSpirulina

Substanzen

Antiviral AgentsInterferon-gamma

Autor:innen und Institutionen

  • National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University MS 38677, USA.
  • National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University MS 38677, USA; Division of Pharmacognosy, Department of BioMolecula…
  • Department of Medicine, University of Mississippi Medical Center, Jackson MS 39216, USA.
  • National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University MS 38677, USA. Electronic address: ndpugh@olemiss.edu.

Förderung

  • NCCIH NIH HHS
  • National Institutes of Health
  • National Center for Complementary and Integrative Health
  • Office of Dietary Supplements
  • USDA Agricultural Research Service

Zitieren

APA

Mir, T. M., Shamim, K., Zhang, J., Khan, S. I., Tripathi, S. K., Khan, I. A., Marshall, G. D., Ashfaq, M. K., & Pugh, N. D. (2024). Immulina® mitigates the development of illness when administered during the prodromal period of influenza viral infection in mice (Part 2). Phytomedicine. https://doi.org/10.1016/j.phymed.2024.155778

Vancouver

Mir TM, Shamim K, Zhang J, Khan SI, Tripathi SK, Khan IA, et al. Immulina® mitigates the development of illness when administered during the prodromal period of influenza viral infection in mice (Part 2). Phytomedicine. 2024. doi:10.1016/j.phymed.2024.155778

BibTeX
@article{Mir2024,
  author = {Mir, Tahir M and Shamim, Kashif and Zhang, Jin and Khan, Shabana I and Tripathi, Siddharth K and Khan, Ikhlas A and Marshall, Gailen D and Ashfaq, Mohammad K and Pugh, Nirmal D},
  title = {Immulina® mitigates the development of illness when administered during the prodromal period of influenza viral infection in mice (Part 2)},
  journal = {Phytomedicine},
  year = {2024},
  doi = {10.1016/j.phymed.2024.155778}
}
Kostenlos starten →